Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration. It develops TR-987, a topical drug in Phase III clinical trial for the treatment of chronic wounds and venous leg ulcers; and TR Pro+, a post-procedure gel for the aftercare of acute wounds, and aesthetic and medical procedures. Tissue Repair Ltd was incorporated in 2012 and is based in Chatswood, Australia.